DAXOR CORP (DXR) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
The company has not diluted shareholders through share issuances in the past 2 years, which is positive for existing holders.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Jan 26, 2026 |
8-K filing: Daxor Corporation issued and sold 765,958 registered shares of common stock at $11.75 per share through a registered direct offering, for net proceeds of approximately $8,142,006, with the closing occurring on January 26, 2026. ($8.14M proceeds) |
N/A | 0 |
| Nov 28, 2023 |
8-K filing: Daxor Corporation raised net proceeds of $3,555,532 through a public offering of 410,260 shares at $9.75 per share on May 22, 2023 and reserved $550,000 for technology development. ($3.56M proceeds) |
N/A | 0 |
| Oct 27, 2023 |
8-K filing: Daxor Corporation is providing additional information regarding the use of proceeds from its public offering on May 22, 2023, where it raised net proceeds of $3,555,532 through the issuance of 410,260 shares at $9.75 per share and has reserved $1,900,000 for continued development of its next generation optical blood volume analyzer systems. ($3.56M proceeds) |
N/A | 0 |
| May 26, 2023 |
8-K filing: Daxor Corporation announced the closing of a public offering consisting of 410,260 shares of its common stock at $9.75 per share, with gross proceeds expected to be $4.0 million. ($4.0M proceeds) |
N/A | 0 |
| Nov 21, 2022 |
8-K filing: Daxor Corporation announced the closing of its underwritten public offering consisting of 210,527 shares of its common stock at a public offering price of $9.50 per share, with the underwriter purchasing an additional 10,523 shares. The aggregate gross proceeds to Daxor are expected to be $2.1 million. ($2.1M proceeds) |
N/A | 0 |